Skip to content

Tack Optimized Balloon Angioplasty (TOBA) Study

Tack Optimized Balloon Angioplasty (TOBA) Study for Femoropopliteal Arteries Using the Tack-IT Endovascular Stapler

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01663818
Acronym
TOBA
Enrollment
138
Registered
2012-08-13
Start date
2012-08-31
Completion date
2015-10-31
Last updated
2021-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Vascular Disease

Brief summary

A multi-center, post-CE Mark study designed to evaluate the performance of the Intact Vascular Tack-IT Endovascular Stapler™ in subjects with vascular flaps (e.g.; post-angioplasty dissection) resulting from percutaneous transluminal balloon angioplasty (PTA) of superficial femoral or popliteal artery(ies).

Detailed description

Intact Vascular intends to conduct a prospective, single arm, multi-center, post-CE Mark study designed to evaluate the performance of the Intact Vascular Tack-IT Endovascular Stapler™ in subjects with vascular flaps (e.g.; post-angioplasty dissection) resulting from percutaneous transluminal balloon angioplasty (PTA) of superficial femoral or popliteal artery(ies).

Interventions

DEVICETack-It Endovascular Stapler

Sponsors

Philips Clinical & Medical Affairs Global
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Rutherford clinical category 2, 3 or 4 * ABI less than or equal to 0.90 * Reference vessel diameter is between 2.5mm and 5.5mm * Target lesion has stenosis greater than or equal to 70% or is occluded * Target lesion is less than or equal to 10cm in length

Exclusion criteria

* Previously implanted stent in the ipsilateral superficial femoral or popliteal artery * Target treatment area is severly calcified (e.g. circumferential calcification or calcium plaque visible on plain fluoroscopy that extends far more than 5.0cm continuously)

Design outcomes

Primary

MeasureTime frameDescription
Safety30 daysComposite of new-onset major device-related adverse events.

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026